Physician profile
Michael B Remines
NPI 1205891942
$4,553.26
in general payments reported to CMS, 2019-2025
45 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $295 · 2021: $342 · 2022: $449 · 2023: $536 · 2024: $1,267 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,909 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.66 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $834.26 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $515.22 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Amgen INC. | $305.46 | 2019-2025 | Otezla, Evenity, Prolia |
| Abbvie INC. | $287.08 | 2019-2024 | |
| Glaxosmithkline, LLC. | $217.45 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $215.26 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.92 | 2019-2021 | |
| Allergan, INC. | $147.45 | 2019-2020 | |
| Pfizer INC. | $139.94 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $127.78 | 2023-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $115.07 | 2024-2025 | |
| Nevro Corp. | $103.04 | 2023-2024 | Senza |
| Merck Sharp & Dohme LLC | $96.23 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $95.34 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.64 | 2019-2025 | Xifaxan |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Remines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.